


What is claimed is:

1. A compound having the structure:



wherein X is $R_1-(R_2)_n$;


R_1 is C_3-C_{20} alkyl, C_4-C_{20} alkenyl or C_2-C_{20} alkynyl;

R_2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulf-oxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, poly-amine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides; and

n is an integer from 0 to about 6.

2. The compound of claim 1 wherein R_1 is C_4-C_{20} alkyl.
3. The compound of claim 1 wherein R_1 is C_5-C_{20} alkyl.

4. A compound having the structure:




- wherein X is $R_1-(R_2)_n$;
 R_1 is C_3-C_{20} alkyl;
 R_2 is NH_2 , imidazole, or N-phthalimido;
Y is a hydroxyl blocking group;
Z is phosphate or an activated phosphate group;
 Q_1 and Q_2 independently are H or a guanosine blocking group; and
n is an integer from 0 to about 6.

5. The compound of claim 4 wherein:
Y is trityl, methoxytrityl, dimethoxytrityl or trimethoxytrityl.

6. The compound of claim 4 wherein:
Z is β -cyanoethyl-N,N-isopropylphosphoramidate.

7. A compound having the structure:




- wherein X is $R_1-(R_2)_n$;
 R_1 is C_3-C_{20} alkyl, C_4-C_{20} alkenyl or C_2-C_{20} alkynyl;
 R_2 is halogen, hydroxyl, thiol, keto, carboxyl,

nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, imidazole, N-phthalimido, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides; and

n is an integer from 0 to about 6.

8. The compound 2'-O-propylguanosine, 2'-O-pentylguanosine, 2'-O-nonylguanosine, 2'-O-octadecylguanosine, 2'-O-(N-phthalimido)-pentylguanosine, or 2'-O-(imidazol-1-yl)butylguanosine.

Sub B2
AT 9. An oligomer comprising at least one subunit having the structure:



wherein X is R₁-(R₂)_n;

R₁ is C₃-C₂₀ alkyl, C₄-C₂₀ alkenyl, or C₂-C₂₀ alkynyl;


R₂ is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, imidazole, N-phthalimido, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule,

conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

T_3 and T_5 independently are OH or a further subunit of said oligomer that is joined to said structure; and

n is an integer from 0 to about 6.

10. An oligomer comprising at least one subunit having the structure:



wherein X is $R_1-(R_2)_n$;


R_1 is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, imidazole, N-phthalimido, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

T_3 and T_5 independently are OH or a further subunit of said oligomer that is joined to said structure; and

n is an integer from 0 to about 6.

11. A method of modulating the synthesis of a protein comprising specifically hybridizing with mRNA coding for said protein an oligomer comprising at least one subunit having the structure:



wherein X is $R_1-(R_2)_n$;

R_1 is C_3-C_{20} alkyl, C_4-C_{20} alkenyl, or C_2-C_{20} alkynyl;


R_2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, imidazole, N-phthalimido, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, and a group that enhances the pharmacokinetic properties of oligonucleotides;

T_3 and T_5 independently are OH or a further nucleotide or nucleoside of said oligonucleotide or oligonucleoside that is joined to said structure; and

n is an integer from 0 to about 6.

12. The method of claim 11 wherein said oligonucleotide is in a pharmaceutically acceptable carrier.

13. A method of modulating the synthesis of a protein comprising specifically hybridizing with mRNA coding for said protein an oligomer comprising at least one subunit having the structure:



wherein X is $R_1-(R_2)_n$;

R_1 is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, imidazole, N-phthalimido, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, and a group that enhances the pharmacokinetic properties of oligonucleotides;

T_3 and T_5 independently are OH or a further nucleotide or nucleoside of said oligonucleotide or oligonucleoside that is joined to said structure; and

n is an integer from 0 to about 6.

14. The method of claim 15 wherein said oligonucleotide is in a pharmaceutically acceptable carrier.

add
a² →
Add
C¹⁷ →
Add
y² →